The liver enzymes’ cytochrome P450 (CYP) group is essential for the metabolism of more than 30 individual drugs. Variability in the gene that codes for the enzyme may influence the productivity of the metamorphosis of the drug. Decreased or inactive CYP enzyme activity may result in reduced drug distribution and elimination, increasing the risk of drug accumulation and overdose. Soon after, scientists used inherited testing to identify the CYP gene variation for longitudinal monitoring and follow-up. Furthermore, pharmaceutical companies are looking into the manner in which their products are metabolized by various CYP enzyme differences [10] .

Clopidogrel acts as a prodrug, and its curative efficiency depends on its enzymatic conversion to the active thiol metabolite H4 [11] . While most of the prodrug is hydrolyzed to an inactive byproduct, its own bioactivation takes place in a two-step process involving several CYP isozymes [12] . CYP2C19 primarily interferes with these two metabolic processes,, leading to the formation of H4, whereas CYP3A4 contributes to the formation of H4 to a lesser extent.

Several studies have examined the biological variation in the CYP enzyme that affects the ability of clopidogrel to suppress platelets. The most stable result is that loss-of-function individual nucleotide polymorphisms (SNPs) in CYP2C192 (rs4244285) and CYP2C193 (rs4986893) result in decreased platelet restraint, increased platelet responsiveness, and an increased risk of significant cardiovascular complications, including stent thrombosis, in individuals undergoing PCI [13] . A meta-analysis of nine analyses (n = 9,685) suggested a gene-dose result surrounded by a discrepancy for the fusion of cardiovascular events: a cy carrier has a hazard ratio of 1.57 (95% confidence range 1.13 - 2.16), whereas a person with a pair of reduced-function alleles has a much greater liability (hazard ratio 1.76, 1.24 - 2.5) . The CYP2C19 17 (rs3758581) polymorphism adds to the enzyme task, which increases the risk of bleeding while also improving efficacy and CV outcomes . The above findings prompted the FDA to revise the clopidogrel labeling together with a box warning stating that caution should be exercised with the reduced function of the CYP2C19 allele.

Clopidogrel is a medicinal product that requires metabolic activation to modify its thiol metabolite, which inhibits platelet activation and collection. The present metabolic method takes place several times, and the CYP2C19 enzyme facilitates this process simultaneously. The difference in CYP2C19 causing the enzyme shortage leads to decreased levels of the active thiol metabolite in circulation, which in turn diminishes platelet suppression. Additionally, they are more likely to experience severe adverse cardiovascular events, especially in those who have previously experienced percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) [15] . Poor metabolizers, whose inherited dual nonfunctioning allele leads to an inactive enzyme, and intermediate metabolizers, whose individual nonfunctioning allele leads to a reduced enzyme product, are also included in the CYP2C19 polymorphism.

An expert panel study from the American College of Cardiology and American Heart Association in 2010 emphasised the impact of CYP2C19 transformation on the therapeutic effectiveness of clopidogrel. The present report played a role in the FDA’s decision to add a warning label stating that persons who are needy metabolizers are likely to suffer subpar curative outcomes scheduled at low stages of the active metabolite. Pharmacogenomic testing is proposed as a way of analyzing persevering responses to the drug, and prasugrel and ticagrelor are recommended for underprivileged metabolizers, which do not depend on CYP2C19 metamorphosis [16] . Furthermore, the principles of the Clinical Pharmacogenetics Applications Consortium (CPIC) have amended the combination of underprivileged and intermediate metabolizers, together with the narrative of acute coronary syndrome (ACS) or transdermal coronary intervention (PCI) transition to other antiplatelet therapies. Although contemporary intelligence may be new, the FDA is not used in academic writing, nor is it familiar with intellectual writing. Even though approximately 20% of patients who undergo PCI with stenting show a reduced response to clopidogrel, these patients are close to an increased risk of stent thrombosis, which can lead to serious fitness problems if not treated. Notably, several household protocols were familiarized within 2015 to screen patients undergoing cardiac catheterization via CYP2C19 pharmacogenomic testing. Similarly, companies such as the Florida Wellness Personalized Medicine Initiative have begun to introduce cosmopolitan CYP2C19 testing as standard practice for certain tolerant societies.

One of the most popular drugs for treating cardiovascular and renal diseases, such as hypertension, diabetes, nephrotic syndrome, heart failure, and acute coronary syndrome, are angiotensin-converting enzyme inhibitors (ACEIs) [17] . In those with hypertension and normotension, ACE inhibitors successfully lower mean arterial pressure in addition to systolic and diastolic blood pressure [18] [19] . Numerous randomized controlled trials have evaluated their effectiveness as antihypertensive agents [20] . One of the four first-line medication classes for people with high blood pressure is ACE inhibitors, according to evidence-based guidelines for managing hypertension published by the Eighth Joint National Commission (JNC8) in 2014 [21] .

Only thiazide diuretics and calcium channel blockers are advised for the Black population, although the other three classes—calcium channel blockers, thiazide diuretics, and angiotensin receptor blockers—are appropriate for the general non-Black population [22] . Guidelines from the American Heart Association/American College of Cardiology (AHA/ACC) and the European Society of Cardiology (ESC) also recommend ACE inhibitors as first-line antihypertensive treatments, particularly for patients with cardiovascular disease and diabetes mellitus [23] [24] . Although ACE inhibitors are helpful, Black hypertension patients have not responded as well to them in clinical settings as white patients [25] .

ACE inhibitor medication has been demonstrated to considerably lower overall mortality since the 1980s in a number of large, prospective, randomised, placebo-controlled trials, particularly in patients with heart failure with a reduced ejection fraction (HFrEF) [26] [27] . Additionally, these trials showed that even in patients with left ventricular failure who do not exhibit any symptoms, ACE medications reduce mortality rates [28] . ACE inhibitors remain the preferred initial treatment for patients with heart failure in view of these strong findings [29] [30] . By decreasing systolic wall stress, preload, and afterload, ACE inhibitors increase cardiac output without raising heart rate, improving the outcomes of heart failure [31] . Additionally, they enhance the hypertrophy of cardiac myocytes [32] [33] .

1) Mechanism of action

Angiotensin II is essential for cardiovascular regulation because it causes precapillary arteriole and postcapillary venule vasoconstriction, inhibits norepinephrine reuptake, promotes catecholamine release from the adrenal medulla, reduces sodium and water excretion, promotes aldosterone synthesis and release, and promotes the hypertrophy of cardiac myocytes and vascular smooth muscle cells [34] [35] . Uncertainty surrounds the precise mechanism of action of ACE inhibitors. The renin-angiotensin-aldosterone system is their primary target, however blood renin levels are not directly correlated with their actions.

In addition to effectively reducing preload and afterload by lowering arterial and venous pressure, ACE inhibitors also work by blocking the angiotensin-converting enzyme, which is responsible for converting angiotensin I into angiotensin II. Another mechanism that has been proposed is that ACE inhibitors interfere with the breakdown of bradykinin, a peptide that induces vasodilation, which results in reduced production of angiotensin II, promotes natriuresis, lowers blood pressure, and prevents remodelling of cardiac myocytes and vascular smooth muscle [36] .

The ratio of angiotensin II’s vasoconstrictive and salt-retentive effects to bradykinin’s vasodilatory and natriuretic effects is regulated by the angiotensin-converting enzyme; ACE inhibitors change this ratio in favour of vasodilation and natriuresis by reducing angiotensin II production and postponing bradykinin breakdown. Although it is unknown how much substance P and other vasoactive chemicals contribute to the positive or negative effects of ACE inhibitors, they also have an impact on their metabolism [37] .

A significant period of time must transpire before perfect anticoagulation with warfarin medication may be obtained, both among different individuals and within the same species, as well as when the drug is replaced with other medicines. Pharmacogenetic modeling of the variability observed in warfarin treatment is based on the interaction between CYP2C9 and VKORC1. The second reaction of humans to warfarin is determined by a heritable mutation in the VKORC1 gene, which controls the oxidation status of vitamin K, whereas the CYP2C9 gene contributes to the transformation of S-warfarin. Pharmacists with experience in cardiology medicine control have been assigned by a number of organizations, including our group, to recommend starting dosages of warfarin that ensure both safety and effectiveness [38] .

The warfarin label is approved by the U.S. According to the Food and Drug Administration (FDA), individuals with the VKORC1 genotype, which is linked to enhanced drug sensitivity, and the CYP2C9 genotype, which is linked to slower drug clearance, should be given lower-than-normal dosages of warfarin. The Pharmacogenetics Applications Consortium (CPIC) has created a pharmacogenomic algorithm that integrates CYP2C9/VKORC1 genotyping consequences with clinical factors equivalent to age and pressure, for the purpose of advising on the choice of medicines. Consequently, several establishments, including ours, have approved a genotype-based warfarin dosage as standard practice [38] .

Beta-blockers compete with catecholamines for binding to the β1-adrenergic receptor, acting as enemies. Angina, myocardial infarction, cardiac arrhythmia, and excessive blood pressure are among the conditions for which they are typically prescribed. Several genes, including CYP2D6, ADRB1, and ADRB2, have been linked to variations in human β-blocker responses. The unfavorable metabolite profile of blockers such as propranolol, timolol, and metoprolol is correlated with differences in CYP2D6 function. Increased drug levels in the circulation occur in 5% - 10% of the societal transport pair, who also possess a greater loss-of-function CYP2D6 allele [39] [40] . However, CYP2D6 polymorphism does not always result in noteworthy clinical outcomes. For example, carvedilol has no effect on CYP2D6 metabolism, whereas several blockers favor atenolol and nadolol. Various conclusions have been drawn from investigations into how common ADRB1 differences affect the blocker response [41] [42] . While some studies have found no significant correlation, others have demonstrated that individuals homozygous for the Arg389 allele have a higher left ventricular ejection fraction than those homozygous for the Gly389 allele do [43] [44] . Neither evidence from cellular probes [45] [46] nor changes in clinical outcomes [47] [48] have been linked to common biological variations in ADRB2.

The FDA’s warning about the ambiguous relationship between CYP2D6 hereditary variation and blocker success is reflected in the label for Lopressor (metoprolol tartrate), which states that CYP2D6-dependent metabolism has no significant effect on the product’s secondary safety or tolerability [49] [50] . However, patients with heart failure who retain the loss-of-function CYP2D6 allele may be at increased risk of excessive drug accumulation and may need to avoid blockers; for a more focused approach to monitoring blocker therapy, pharmacogenomic interactions between blockers and heritable ADBR1 discrepancies may be observed [51] [52] .

3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the enzyme that limits the rate at which cholesterol is synthesized in the liver. By blocking HMGCR, statins, a commonly prescribed type of cholesterol-lowering medication, lower the levels of low-density lipoprotein (LDL) and circulating cholesterol. Many people use statins to avoid CVD, both directly and indirectly because of this mechanism. Significant interindividual diversity in response has been noted, although massive randomized controlled trials (RCTs) have continuously demonstrated their effectiveness. In certain people, this variability may result in inadequate cholesterol reduction and an inability to avoid cardiovascular events . To further understand the genetic basis of this variance in statin efficacy and tolerance, pharmacogenomic studies have been conducted .

1) SLCO1B1

The solute carrier organic anion transporting polypeptide 1B1 (OATP1B1), which is encoded by the SLCO1B1 gene and promotes the hepatic absorption of statins from the portal circulation, is known to be a substrate of statins [54] . Previously known as OATP-C (also known as SLC21A6, OATP2, and LST1), our lab was the first to identify and introduce the nomenclature (range from 1a-14) for SLCO1B1 in 2001. We also determined the functional importance of this nomenclature [55] . Specifically, SLCO1B15 variation leads to decreased membrane localization of OATP1B1, and clinical studies have consistently associated this single-nucleotide polymorphism (SNP) with altered statin disposition. This leads to lower hepatocellular uptake and greater systemic drug exposure. In contrast, decreased plasma statin concentrations have been linked to the SLCO1B11b genotype.

Nonetheless, there is still debate on how well SLCO1B1 variations predict LDL-lowering effectiveness, which calls for more studies with bigger patient populations [56] [57] . Crucially, using statins can cause unanticipated muscle damage, which can range from minor myalgia to potentially fatal rhabdomyolysis. A recent genome-wide association study (GWAS) found that the SLCO1B15 allele is the most reliable predictor of simvastatin-induced myopathy, providing the strongest evidence to date . According to this investigation, the odds ratio for the risk of myopathy caused by SLCO1B15 was 16.9 for homozygous carriers and 4.5 for heterozygous carriers .

Furthermore, in individuals on atorvastatin, simvastatin, or pravastatin, SLCO1B1 5 has been connected to statin-related adverse drug reactions (ADRs), including discontinuation, creatine kinase increase, and myalgia, as well as statin intolerance, which includes dose modifications and statin switching [59] [60] . All of these results show that SLCO1B1 SNPs affect the pharmacokinetics and pharmacodynamics of statins, which leads to statin-induced adverse drug reactions. Notably, different statins have different risks of myopathy; simvastatin has the highest risk, followed by atorvastatin, pravastatin, rosuvastatin, and fluvastatin [61] . In order to minimise the risk of statin-induced myopathy and optimise cholesterol-lowering medications, genotyping for SLCO1B1 SNPs may be helpful.

2) HMGCR and APOE

The pharmacodynamic response to statins, particularly the lowering of LDL, is influenced by genetic differences in HMGCR and APOE. According to LDL reduction, carriers of the HMGCR H7 haplotype, which is identified by three intronic SNPs (rs17244841, rs3826662, and rs17238540), demonstrated an 11% - 19% decreased sensitivity to statins [62] . These results, however, were not confirmed in a GWAS that looked into atorvastatin response . It is currently unclear how the three main APOE haplotypes (rs429358 and rs7412) relate to the statin response. According to a preliminary GWAS on statin response, APOE polymorphisms affected the effectiveness of LDL-lowering medications, with the ε2 haplotype exhibiting the greatest response and variant carriers showing reduced efficacy , but a subsequent meta-analysis was unable to confirm these associations [64] . To fully understand how genetic differences in APOE and HMGCR affect the effectiveness of lipid-lowering medications, more research is required.

3) Kinesin-Like Family 6 (KIF6)

A new mechanism affecting cardiovascular outcomes may be revealed by the KIF6 gene, a member of the kinesin-like family that has been connected to an elevated risk of coronary artery disease (CAD) [65] . Certain studies suggest that carriers of the rs20455 SNP in KIF6 may derive greater cardiovascular benefit from statin therapy than noncarriers do [66] . However, a meta-analysis involving major lipid-lowering trials revealed no substantial correlation between the risk of CVD and this SNP [67] , nor did it reveal differences in statin efficacy between carriers and noncarriers. Thus, more investigation is required to clarify how KIF6 affects cardiovascular outcomes.

a) Role of Transporters and Regulatory Guidance

Strong evidence supports the role of pharmacogenetic variation in drug transporters in influencing the statin response . However, evidence for ancestry-specific genetic markers that predict both lipid-lowering efficacy and cardiovascular risk reduction remains limited and inconclusive. Some research groups have proposed the use of transporter gene polymorphisms to guide individualized statin dosing .

The SLCO1B1 gene, in particular, has been well studied. Its SLCO1B15 allele is closely linked to a higher incidence of myopathy brought on by simvastatin, and this association has been replicated across multiple clinical trials. While similar associations have not yet been established for other statins, the U.S. Food and Drug Administration (FDA) has responded by revising the simvastatin prescribing label, recommending alternative therapies for patients homozygous for SLCO1B15, and advising against prescribing 80-mg doses of simvastatin in this group.

b) Global Regulatory Support for Pharmacogenomics

Since 2013, the FDA has encouraged the integration of pharmacogenomics (PGx) into early clinical drug development. In parallel, the European Medicines Agency (EMA) has revised its guidelines to incorporate DNA sample collection and genomic data throughout all phases of clinical development [69] . According to research, drugs with supporting genetic evidence have a clinical success rate that is more than double that of those without such evidence [70] .

Given the high attrition rate in drug development—where over 90% of investigational drugs fail to reach the market the adoption of genetically informed strategies is crucial to improving outcomes. In fact, approximately 80% of members of the Pharmacogenomics Working Group (I-PWG) report the use of next-generation sequencing (NGS) as part of standard practice in clinical trials.

4) Rosuvastatin

Rosuvastatin has been identified as a substrate for the efflux transporter BCRP, which is encoded by the ABCG2 gene and expressed on the apical membrane of hepatocytes. The ABCG2 421C a polymorphism has been linked to rosuvastatin pharmacokinetics and an enhanced LDL-lowering response [68] . Notably, the observed LDL reduction in carriers of this variation was comparable to that achieved with double the usual rosuvastatin dose. Atorvastatin and simvastatin are largely metabolized by CYP3A4, and frequent polymorphisms in CYP3A4 may alter their pharmacokinetics and therapeutic response. Statin medication also leads to the overexpression of the LDL receptor (LDLR) [69] [70] . LDLR haplotypes have been linked to decreased statin efficacy in populations with African heritage. Additionally, in a combined GWAS of three trials, carriers of the rs8014194 polymorphism in the CLMN gene, which encodes the calmin protein of uncertain function, presented a 3% greater reduction in total cholesterol than noncarriers did [70] [71] .

5) Clinical Implementation

The most robust evidence supporting the clinical relevance of statin pharmacogenetics pertains to genetic variations in drug transporters. However, strong evidence for other genetic markers associated with statin response and myopathy risk remains limited and requires further validation. As a result, several research groups have advocated the use of transporter polymorphisms to guide statin dosing [58] . The U.S. Food and Drug Administration (FDA) has updated the label for simvastatin to incorporate SLCO1B1-defined guidelines, advising prescribers to avoid prescribing 80 mg of simvastatin to homozygous SLCO1B15 carriers and to consider alternative statin options, although the association between the SLCO1B15 genotype and simvastatin-induced myopathy has been confirmed in multiple clinical studies (although similar associations with other statins are less well established). Summary of key pharmacological markers in cardiovascular medicine are provided in Table 1 .

With a high attrition rate in drug development, in which more than 90% of drugs fail during the process [72] , effective methods are needed to increase success rates. Studies have shown that drugs supported by genetic evidence have more than twice the likelihood of clinical success [73] . In 2013, the FDA issued industry guidance on clinical pharmacogenomics (PGx) and early-phase clinical studies [74] . Both the European Medicines Agency (2018) and the FDA (2013) have recommended the collection of DNA samples throughout all phases of clinical development. The genomic characterization of clinical trial participants has become standard practice, with approximately 80% of Industry Pharmacogenomics Working Group (I-PWG) members reporting the use of next-generation sequencing [75] . While relatively few studies have focused on traditional PGx markers related to drug metabolism, there is a growing emphasis on biomarkers for targeted therapy, a key aspect of precision medicine. Most genetic characterization of trial participants occurs in oncology studies, although other therapeutic areas—including cardiovascular diseases, neuroscience, immunology, and rare diseases—are also increasingly incorporating genomic insights.

Integrating pharmacogenomic data into a clinical trial design allows for a more personalized approach to drug evaluation. By identifying genetic subgroups with a greater likelihood of responding to a specific treatment, researchers can develop more efficient and targeted trials, ultimately reducing both the time and cost associated with drug development [76] .

The mapping of the human genome and developments in next-generation sequencing (NGS) have been major factors in the development of precision medicine [76] [77] . The capacity to swiftly and thoroughly identify genetic traits, including mutations, rearrangements, and copy number changes, has significantly improved due to advancements in sequencing technologies [78] . Understanding possible biological phenotypes in diseases and working to target these phenotypes specifically served as the foundation for precision medicine.

Precision medicine, in which treatments are customized according to genetic changes, has advanced as a result of these developments. For instance, almost 36% of patients with advanced malignancies had treatable genetic alterations, according to a prospective clinical sequencing study of 10,000 patients at the Memorial Sloan Kettering Cancer Centre (MSKCC) [79] [80] . Additionally, advances in drug development that target genetic changes specific to a disease have aided in the expansion of biomarker-guided therapies, which began in oncology but have since spread to other clinical areas, such as diabetes, CVD, kidney disorders, and neurological conditions [81] - [84] .

CRISPR-Cas9 has transformed translational medicine by bridging the gap between basic research discoveries and therapeutic applications. Although new insights into how genes work have changed treatment approaches, problems such as off-target effects and limitations in altering particular genomic regions still plague gene editing technology. However, the development of CRISPR-Cas9 offers a potential remedy. Because it allows for precise gene editing, this extremely adaptable technology is especially useful for the genomic alterations needed for clinical interventions [85] .

Important risk variables like inflammation, arterial calcification, and plasma lipoprotein levels are influenced by genetic differences, including mutations and frequent polymorphisms . Heritability estimates for coronary atherosclerosis, which are based on fatal cardiac events, range from 38% to 57%, which is further supported by twin studies [87] . Genetic factors play crucial roles in many cardiovascular diseases, making them strong candidates for CRISPR-Cas9-based therapies. The heritability estimate for advanced atherosclerosis, the primary cause of coronary artery disease (CAD), ranges from 40% to 70%, indicating a significant genetic contribution to disease pathology .

Mutations in the LDLR gene are the main cause of familial hypercholesterolaemia (FH), the most common monogenic disorder linked to early cardiovascular disease (CVD), which affects approximately 1 in 200 people. Approximately 1000 pathogenic LDLR mutations out of more than 2900 have been detected. Similarly, mutations in more than 11 sarcomeric genes—of which more than 1400 variations have been found—are connected to hypertrophic cardiomyopathy (HCM), which affects 1 in 500 people [88] . Furthermore, the majority of arrhythmia syndromes are autosomally inherited, meaning that first-degree relatives have a 50% probability of experiencing the ailment [89] . A major risk factor for cardiovascular diseases, hypertension, is also significantly influenced by genetics. One of the most well-researched genes associated with blood pressure regulation is the AGT gene, which codes for angiotensinogen. Variations in AGT are associated with raised angiotensinogen levels and an increased risk of hypertension, highlighting the potential of genetic interventions in the treatment of this condition [90] . Heritability estimates for blood pressure range from 30% to 50%. Furthermore, cardiovascular complications like arrhythmias and cardiomyopathy affect about 40% of individuals with mitochondrial diseases; of these, cardiomyopathy is the most prevalent, affecting 20% - 25% of adults with mitochondrial disorders, while arrhythmias and conduction defects, like AV block and atrial fibrillation, occur in 26% of cases. This shows how mitochondrial genetic defects significantly contribute to the development of cardiovascular disease [91] .

Genomic editing has considerable potential for directly correcting single-gene abnormalities that contribute to certain CVDs, presenting a promising approach for therapy and even the potential eradication of specific disease forms [92] . Furthermore, the development of CRISPR-Cas9 systems that rely on transitory protein regulation rather than permanent genetic modifications has increased the therapeutic value of these methods. The successful insertion of advantageous genes into early human embryos at the zygote stage [93] indicates that the use of CRISPR-Cas9 in human systems is feasible. The main uses of CRISPR-Cas9 are examined in this section, with an emphasis on mitigating mitochondrial dysfunction, controlling protein expression, and fixing genetic abnormalities.

Therapeutic use of CRISPR-Cas9 in CVD represents an evolutionary advance in precision medicine, as it allows direct editing of disease-causing pathogenic genetic variants [94] . Multiple cardiovascular diseases have distinct inheritance, with certain genes playing key roles in their etiology and progression. Familial hypercholesterolemia (FH), for instance, is strongly linked with mutation in the lipoprotein receptor gene LDLR and is one of the most important targets for heritable genome editing [95] . Since low-density lipoprotein (LDL) is directly implicated in the development of atherosclerosis, therapies lowering LDL have immense therapeutic power in lowering overall cardiovascular risk. Management of atherosclerosis—a systemic inflammatory vascular condition that accounts for more than one-quarter of global mortality—requires drugs that, concurrently, reduce LDL and triglycerides and elevate protective high-density lipoproteins (HDL) [96] [97] . Atherosclerosis is characterized by the accumulation of fibrofatty plaques in vessel walls, and left untreated, can progress to fatal states such as ischemic stroke, myocardial infarction, peripheral artery disease, and even psychological distress related to chronic illness [98] - [100] .

One of the more well-characterized FH-associated mutations is LdlrE208X, the murine homologue of the human E207X mutation. This nonsense mutation creates an early stop codon, interfering with LDL receptor function, lowering LDL clearance, and enhancing atherosclerosis. In a model study, Zhao et al. used adeno-associated virus serotype 8 (AAV8) to deliver CRISPR-Cas9 to a mouse model carrying this mutation. The therapy partially restored LDL receptor function, reduced macrophage infiltration, lessened plaque area, and exhibited a dramatic reduction in total cholesterol, LDL, and triglycerides, all without major off-target effects, thereby establishing efficacy and safety [101] .

Outside of FH, CRISPR-Cas9 has been successfully used in genetic cardiomyopathies. Dilated cardiomyopathy (DCM), found in approximately one in every 250 people, is characterized as dilation of the ventricles, abnormal contractility, and high mortality [102] . One of the largest advances was the creation of the ABEmax-VRQR-SpCas9 base-editing platform, which was used to edit disease-inducing mutations within the RBM20 gene (particularly RBM20R634Q and RBM20636). Editing iPSCs and grafting them into mouse heart tissue corrected pathologic dilation, restored contractile function, and prolonged survival, while untreated models experienced progressive ventricular enlargement [103] . Editing the TTN gene encoding titin also corrected function of sarcomeres in human iPSC-derived cardiomyocytes, further illustrating the potential of CRISPR to correct structure and function deficits [104] .

CRISPR has also revealed viral cardiomyopathy mechanisms. Genome-wide screens identified ADAM9, a metalloproteinase necessary for EMCV infection, as a therapeutic target [105] . In hypertrophic cardiomyopathy (HCM), CRISPR-Cas9 was employed to knock out the MYH6 R403Q mutation using AAV9 vectors, deleting the defective allele in over 70% of cardiomyocytes and halting disease progression [106] [107] . Some of the other examples include the correction of LZTR1 Noonan syndrome mutations [108] , MYBPC3 embryonic mutation correction that is linked with HCM [109] , and therapeutic PRKAG2 allele knockout in cardiac syndromes [110] [111] . In addition, AAV9-delivered CRISPR elimination of the RYR2 R176Q allele suppressed catecholaminergic polymorphic ventricular tachycardia (CPVT) [112] , and PLN R14del mutation correction normalized calcium control and reduced arrhythmogenic risk [113] .

Finally, CRISPR has been directed against Duchenne muscular dystrophy (DMD), a fatal X-linked illness defined by dystrophin deficiency [103] . Using AAV9 vectors and an engineered CRISPR system to induce exon skipping, researchers corrected as much as 90% of dystrophin expression in cardiac muscle, improving cardiac and skeletal muscle function. Significantly, gene correction was observed following four weeks, emphasizing the rapid therapeutic response of CRISPR-Cas9 against deforming inherited disorders.

Pharmacogenomics, the study of how a human’s inherent makeup affects his or her response to a medicinal product, is a key avenue for advanced personalized medicine. However, the integration of pharmacogenomic knowledge into the clinical workflow is hindered by significant impediments, including difficulties in data collection, decision-making, and execution [114] . The related interactions among genes and drugs highlight the need for sophisticated instruments to predict and determine the manner in which individuals respond to multiple medicines [115] . In light of the above, intelligent automation (automated reasoning) and machine learning are essential opportunities to overcome the obstacles mentioned above and accelerate the development of personalized healthcare services [116] .

AI’s use in cardiovascular medicine has been a primary development in the field of cardiovascular medicine. The use of automated reasoning in correct medicine has markedly increased society genetics [117] . The synergies of artificial intelligence, enormous facts, and precision of medicine have been crucial for the creation of innovative medicines, helping to design productive treatments during the minimization of the risk of undesirable effects in humans. A number of CV medicines, including clopidogrel, warfarin, and lipid-lowering medicines, notably simvastatin, are currently being studied as curative targets [118] .

Pharmacogenomics and precision medicine have already resulted in a significant discrepancy between the dose of warfarin and the various survival categories, as demonstrated by the randomized clinical trials performed by Pirmohamed et al. and Syn et al. Pirmohamed et al. have revealed that patients who have received a warfarin dose established on a pharmacogenetic basis remain within a curative transnational normalization ratio (INR) variety longer than those receiving standard doses [119] . Similarly, Syn et al. produced comparable findings in a population of Asians taking warfarin. In addition, Li et al. used a backpropagation nervous system on the Web to predict the warfarin dose for patients who would undergo soul valve replacement [120] . Moreover, AI-enhanced deep learning structures are ready to revolutionize drug discovery, personalized drug therapy, and precision medicine.

AI has developed innovative systems for measuring cardiovascular risk and heart disease, managing hypertension, and improving pharmacologic therapy. Shah et al. implemented corrective medicine approaches to clarify the mechanism underlying cardiac catastrophe and revealed a recent classification of emotion failure together with preserved expulsion fraction (HFpEF) [121] . This classification was improved by the use of ‘‘phenomapping’’, an AI-based unsupervised deep learning technique that combines extensive tolerant facts, including clinical evaluation, laboratory consequences, echocardiogram, and image analysis.

Shah et al. reported three phenogroups associated with HFpEF. Phenogroup 1 (natriuretic peptide deficiency syndrome phenotype) is a young patient with fleshiness, few cardiac abnormalities, minimal brain natriuretic peptide (BNP) levels, and primarily beneficial effects [122] . Phenogroup 2 (obesity-cardiometabolic phenotype) was characterized by a high incidence of diabetes and corpulence, increased BNP tiers, and impaired left ventricular relaxation (defined by the last rate of vitamin E on echocardiography). Phenogroup 3 (cardierative phenotype) has a high incidence of electrocardiographic and echocardiographic abnormalities, together with kidney disease and a poor prognosis. Phenotyping of HFpEF patients could facilitate the development of targeted drug therapy and help in the design of upcoming clinical tests, which would indicate a patient’s favorable response to detailed treatment [123] . Additionally, Przewlocka-Kosmala et al. [124] examined the relationship between exercise intolerance and ventricular systolic modesty function in HFpEF patients using machine learning. These findings suggest that poor modesty capacity is linked to lower left ventricular systolic function. There are still new opportunities for drug research and optimisation thanks to machine intelligence. See Figure 1 and Table 2 .

By combining various patient, pharmacogenomic, and population-level data into meaningful insights for healthcare delivery, AI is transforming clinical practice. Precision diagnosis, risk assessment, and therapy optimisation are made possible in cardiovascular medicine by AI-driven algorithms that evaluate complicated datasets like imaging, genetic profiles, laboratory results, and electronic health records. AI and pharmacogenomics improve drug response prediction, reduce side effects, and direct individualised treatment. Models for allocating resources and preventing disease are further improved by cohort and population data. AI helps with phenotyping, medication discovery, and clinical decision-making in real time in addition to diagnostics. Improved patient outcomes, cost effectiveness, and a shift towards individualised, predictive, and preventive cardiovascular care are all guaranteed by this smooth integration of AI into clinical operations.